Acticor Biotech, a clinical-stage biopharmaceutical company developing glenzocimab for cardiovascular emergencies, faces liquidation as the court-appointed administrator has requested the conversion of its receivership proceedings. The Paris Commercial Court will address this request on December 19, 2024. This situation arises after glenzocimab failed to demonstrate significant neurological improvement in stroke patients during three international clinical trials.
This potential liquidation represents a significant setback for the acute ischemic stroke treatment landscape. Glenzocimab, designed to target the GPVI platelet receptor without increasing bleeding risk, held promise as a safer alternative to existing therapies. The failure of the drug to meet its primary endpoint in clinical trials highlights the challenges in developing effective stroke treatments and may impact investor confidence in similar approaches. The unmet need for safer and more effective acute ischemic stroke treatments remains substantial, leaving a void in the market.
Acticor Biotech, founded in 2013, tested glenzocimab in over 800 subjects across various clinical trials, including studies for stroke and myocardial infarction. While the stroke trials did not achieve their primary neurological improvement goals, a sub-group analysis revealed a significant reduction in mortality among patients with intracerebral haemorrhage. Furthermore, the LIBERATE Phase 2 trial, focused on myocardial infarction, is ongoing. Financially, the company has been supported by various European and international investors and has been listed on Euronext Growth Paris since November 2021. The intellectual property related to glenzocimab is protected by patent families extending to 2036.
The impending liquidation of Acticor Biotech underscores the inherent risks in the biotechnology industry. While the future of glenzocimab remains uncertain, the data from the completed trials, particularly the mortality reduction observed in the intracerebral haemorrhage subgroup, could potentially be leveraged for future research or alternative applications. The outcome of the court decision will determine the fate of Acticor Biotech’s assets and intellectual property, potentially impacting future development in this therapeutic area. The liquidation also signifies a loss for investors and highlights the need for continued investment and innovation in the search for effective cardiovascular emergency treatments.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
